Figure 2.
Consort diagram of patient flow. Twenty patients were enrolled in the study and underwent leukapheresis. NS7CAR T cells were successfully manufactured and infused into all patients at a low dose (0.5 × 106/kg, n = 3), medium dose (1-1.5 × 106/kg, n = 16), or high dose (2 × 106/kg, n = 1). All were available for day 28 evaluation after NS7CAR T-cell infusion.

Consort diagram of patient flow. Twenty patients were enrolled in the study and underwent leukapheresis. NS7CAR T cells were successfully manufactured and infused into all patients at a low dose (0.5 × 106/kg, n = 3), medium dose (1-1.5 × 106/kg, n = 16), or high dose (2 × 106/kg, n = 1). All were available for day 28 evaluation after NS7CAR T-cell infusion.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal